e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
COPD: new markers of diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Similar adaptive immune response in COPD patients with and without alpha1 antitrypsin deficiency
S. Baraldo, E. Bazzan, G. Turato, B. Molena, F. Lunardi, N. Nannini, M. Damin, M. Schiavon, E. Balestro, M. Loy, F. Rea, M. Cosio, F. Calabrese, M. Saetta (Padova, Italy; Monetreal, Canada)
Source:
Annual Congress 2013 –COPD: new markers of diseases
Session:
COPD: new markers of diseases
Session type:
Thematic Poster Session
Number:
599
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Baraldo, E. Bazzan, G. Turato, B. Molena, F. Lunardi, N. Nannini, M. Damin, M. Schiavon, E. Balestro, M. Loy, F. Rea, M. Cosio, F. Calabrese, M. Saetta (Padova, Italy; Monetreal, Canada). Similar adaptive immune response in COPD patients with and without alpha1 antitrypsin deficiency. Eur Respir J 2013; 42: Suppl. 57, 599
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Identification of novel pathogenic mechanisms triggered by arginase activation in patients with COPD
Source: International Congress 2016 – Airway response to infection
Year: 2016
Imbalance of immune response functional phenotype and alveolar macrophages phenotype in COPD
Source: International Congress 2014 – New insights into monocyte and macrophage biology
Year: 2014
B cells in a murine model of allergic asthma and respiratory tolerance
Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions
Year: 2015
Evaluation of protease-antiprotease imbalance in moderate COPD without antitrypsin deficiency
Source: International Congress 2015 – Modulating the immune system in COPD and asthma
Year: 2015
Expression of vascular remodeling markers in relation to bradykinin receptors in asthma and COPD
Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases
Year: 2013
Blood T regulatory lymphocytes number is decreased in severe COPD
Source: Annual Congress 2013 –COPD: new markers of diseases
Year: 2013
Evidence for cell mediated immune dysfunction in the COPD lung: The role of cytotoxic CD4+ T cells
Source: International Congress 2015 – Viral infections: basic research and clinical perspective
Year: 2015
PTX3 a marker of innate immune responses in the airways of asthmatics and COPD patients
Source: Annual Congress 2013 –Asthma: new mechanisms and markers
Year: 2013
Sputum cell mRNA transcripts demonstrate alteration of endothelin metabolism in severe asthma and COPD
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013
Investigation the role of pentraxin-3 in the innate immune system in patients with COPD
Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease
Year: 2015
Humoral immunity parameters in smoking and non-smoking patients with COPD
Source: International Congress 2014 – Translational studies in COPD
Year: 2014
Lymphocyte senescence in COPD is associated with loss of glucocorticoid receptor expression by cytotoxic/ pro-inflammatory lymphocytes
Source: International Congress 2014 – Effect of cigarette smoke on cell behaviour: cell biology, signalling and senescence
Year: 2014
Specific airway resistance as a marker of early disease in alpha-1 antitrypsin deficiency
Source: International Congress 2015 – Lung function: exploring the boundaries of the respiratory system
Year: 2015
LATE-BREAKING ABSTRACT: Interleukin-33 augments rhinovirus-induced type 2 immune responses in people with asthma, but not in healthy donors
Source: International Congress 2015 – Emerging strategies for airway disease treatments
Year: 2015
Elevated IL-17A in very severe COPD is localized to mast cells and correlates with lung function decline
Source: International Congress 2014 – TH17 and other acute asthmatic responses
Year: 2014
LATE-BREAKING ABSTRACT: BAFF: a self-perpetuating mechanism of B cell activation in COPD
Source: International Congress 2014 – COPD physiopathology
Year: 2014
Autoreactivity in patients with combined COPD and asthma phenotype
Source: International Congress 2014 – Novel approaches to human studies in allergy and asthma
Year: 2014
T regulatory cells: Immunomodulation by budesonide and formoterol on COPD patients
Source: International Congress 2015 – Mucosal immunology: what’s new in 2015
Year: 2015
Cellular mechanisms underlying CCSP SNP association with chronic airway diseases
Source: International Congress 2015 – New models for treating airway diseases
Year: 2015
Airway inflammation in patients with different levels of asthma control
Source: Annual Congress 2013 –Asthma: new mechanisms and markers
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept